Novo Nordisk’s Legal Blitz and Discounted Ozempic Copy Signal a New Phase in the GLP-1 Wars

Novo Nordisk sues Eli Lilly over misleading ads, fights copycats, and launches a cheaper Ozempic in South Africa amid GLP-1 market pressures and a 27% YTD stock drop.

The Danish pharmaceutical giant is firing on multiple fronts — in the courtroom, on the pricing front, and across emerging markets — as it fights to defend its dominant position in the $100 billion-plus GLP-1 market. Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing its biggest rival of running television advertisements that rely on “knowingly outdated” clinical data to make Zepbound appear superior to Wegovy. The complaint, lodged on July 21, alleges that Lilly’s commercials compare low Wegovy doses with the highest approved Zepbound dose, a tactic Novo Nordisk argues is fundamentally misleading. The company is seeking a permanent injunction against the ads plus unspecified damages. Lilly has pushed back, vowing to contest the claims.

The legal offensive does not stop there. Novo Nordisk also sued Hims & Hers in February over what it describes as unauthorized compounded versions of its semaglutide drugs, pointing to FDA concerns about purity and dosing accuracy. Hims & Hers shares tumbled roughly 16 percent when the suit became public. In South Africa, a court has already barred the supplier iDexis from manufacturing compounded semaglutide, and the country’s health regulator SAHPRA ordered a recall of those products.

Yet Novo Nordisk is simultaneously expanding access to its own branded medicine through an unconventional channel. Starting this week, the company is rolling out a cheaper authorized copy of Ozempic in South Africa in partnership with Acino. Unlike a generic, this version is manufactured by Novo Nordisk itself — identical active ingredient, same production process, and the same injection device, just sold under a different name. The move is designed to capture price-sensitive patients in emerging markets without undermining the premium brand elsewhere.

The dual strategy — aggressive litigation against copycats while offering a licensed discount version — reflects the complexity of Novo Nordisk’s current position. The stock has shown resilience in recent sessions, closing at €43.35 on the day, up 1.17 percent, and gaining 2.92 percent over the past 30 days. But the longer-term picture is sobering: the shares remain 27.22 percent lower year-to-date, a hangover from intensifying GLP-1 competition that has weighed on the entire sector. The stock now trades roughly 41 percent above its March low, suggesting a tentative stabilization after a brutal sell-off.

Analyst sentiment is divided. Willow Tree Research initiated coverage with a buy rating and a $68 price target, pointing to the oral Wegovy pill, the pipeline including high-dose Wegovy, CagriSema, and Zenagamtide, and the potential to expand the addressable obesity market. Risks cited include competition, pricing pressure, and the 2032 U.S. patent expiry for semaglutide. A more cautious view rates the stock a “hold,” noting that adjusted revenue fell 10.3 percent year-on-year, dragged down by weakness in Ozempic and Rybelsus, and that near-term pipeline catalysts are thin. Goldman Sachs cut its price target from 400 to 260 Danish kroner in March, while Citi raised its target from 290 to 330 Danish kroner but kept a “neutral” rating. The wide spread in analyst expectations underscores the uncertainty around how the legal and commercial battles will play out.

The EU approval of the oral Wegovy pill on July 15 provided a short-term lift, with the U.S.-listed shares popping on the news. In the pivotal OASIS study, the 25-milligram dose delivered 17 percent weight loss versus 3 percent with placebo. That regulatory win is critical, because Novo Nordisk has guided for a 5 to 13 percent revenue decline in 2026, pressured by U.S. price cuts, patent expirations, and mounting competition from Lilly and others. The semaglutide patent runs through 2032 in the U.S. and 2033 in Europe and Japan, giving the company a limited window to maximize returns before the generics floodgates open.

For now, the market is watching whether Novo Nordisk’s courtroom victories can translate into market share protection — and whether the South Africa experiment with authorized copies can be replicated in other price-sensitive regions without cannibalizing premium sales. The next major catalyst will be the quarterly results, due in early August, which will show whether the operational headwinds are easing or intensifying.